RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Testing a scan for clumped Parkinson’s-related protein

Researchers study whether a new imaging substance can detect accumulated alpha-synuclein protein in Parkinson’s and related conditions.

Testing a treatment or activity · Study reference: NCT06098612

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2024-05-01
Main measurements finished (planned)
2026-11
Study finished (planned)
2027-11

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 50 years to 80 years · Also accepts healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * General Inclusion criteria, all subjects must: 1. Age 50-80 2. Be able to provide written informed consent or assent 3. Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary) 4. Be willing and able to participate in one PET/MRI scanning session Additional Inclusion criteria for PD patients, subjects must: 1. Have an existing diagnosis of idiopathic PD, using consensus criteria 2. Stable medications for at least 30 days 3. Hoehn and Yahr stage I-IV 4. A study partner who can answer questions pertaining to daily functioning Additional Inclusion criteria for MSA patients, subjects must: 1. Have an existing diagnosis of MSA, using consensus criteria 2. Stable medications for at least 30 days 3. MSAp or MSAc 4. A study partner who can answer questions pertaining to daily functioning Additional Inclusion criteria for DLB patients, subjects must: 1. Have an existing diagnosis of probable DLB, using consensus criteria 2. Stable medications for at least 30 days 3. Clinical Dementia Rating Scale (CDR) \< 0.5 4. A study partner who can answer questions pertaining to daily functioning Exclusion Criteria: * General Exclusion Criteria (All Subjects) 1. History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled 2. Major psychiatric disease (e.g.schizophrenia) 3. History of stroke 4. Focal brain lesions on MRI scans 5. History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness 6. Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months 7. History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile) 8. Impaired elimination (as defined as having problems with urination) unless being managed 9. Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed) 10. Any present substance abuse including drug/alcohol abuse 11. Inability to lie flat on camera bed for up to 90 min 12. Pregnancy or breastfeeding 13. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan 14. Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts) General MR and PET safety exclusion criteria listed below 1. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing 2. Electrical implants such as cardiac pacemakers or perfusion pumps 3. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest 4. Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis) 5. Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential 6. Body weight of \> 300 lbs (weight limit of the MRI table) 7. Breast feeding mothers Exclusion Criteria for Subjects Undergoing Blood Draws Through an Arterial Line During PET Scan 1. An abnormal result on the modified Allen's test on both hands 2. Raynaud syndrome 3. Bleeding disorder 4. Use of anticoagulants such as Coumadin, Plavix or Lovenox 5. An allergy to Lidocaine
Full study name & original research details

Official study title

PET Imaging Evaluation of [11C]SY08

Original description

The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.

Conditions reported: Parkinson's Disease; Multiple System Atrophy; Dementia With Lewy Bodies; Healthy Controls

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
C11-SY08
Phases
EARLY_PHASE1
Sponsor
Massachusetts General Hospital
Start date reported by registry
2024-05-01 (actual)

Registry updated: 2025-12-24 · Status last verified by the registry submitter: 2025-12

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Changning Wang, PhD · 6177243983 · cwang15@mgh.harvard.edu

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

MGH

Charlestown, Massachusetts, United States

Recruiting

Changning Wang · 617-724-3983 · cwang15@mgh.harvard.edu

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.